» Articles » PMID: 22135743

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects

Overview
Journal Pulm Med
Publisher Wiley
Specialty Pulmonary Medicine
Date 2011 Dec 3
PMID 22135743
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We present novel data demonstrating that the expression of PPARγ is reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients. Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from white, but not black, SSc-ILD patients. Blocking the c-Met receptor abolishes rosiglitazone's effects on collagen and MMP-1 in lung fibroblasts isolated from white SSc-ILD patients, while augmenting the expression of the c-Met receptor in fibroblasts from black SSc-ILD patients replicates the effects of rosiglitazone seen in whites. We conclude that PPARγ agonists warrant consideration as potential antifibrotic drugs in patients with SSc-ILD. Differential therapeutic effects might be anticipated especially relative to racial differences and the functional expression of the c-Met receptor.

Citing Articles

Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease.

Cerro-Chiang G, Ayres M, Rivas A, Romero T, Parker S, Mastali M Sci Rep. 2023; 13(1):8645.

PMID: 37244972 PMC: 10224939. DOI: 10.1038/s41598-023-35840-y.


Serum Adiponectin, a Novel Biomarker Correlates with Skin Thickness in Systemic Sclerosis.

Leodori G, Pellicano C, Basile V, Colalillo A, Navarini L, Gigante A J Pers Med. 2022; 12(10).

PMID: 36294874 PMC: 9604668. DOI: 10.3390/jpm12101737.


Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists.

Lecarpentier Y, Gourrier E, Gobert V, Vallee A Front Pediatr. 2019; 7:176.

PMID: 31131268 PMC: 6509750. DOI: 10.3389/fped.2019.00176.


Drugs and Targets in Fibrosis.

Li X, Zhu L, Wang B, Yuan M, Zhu R Front Pharmacol. 2017; 8:855.

PMID: 29218009 PMC: 5703866. DOI: 10.3389/fphar.2017.00855.


Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target.

Marangoni R, Masui Y, Fang F, Korman B, Lord G, Lee J Sci Rep. 2017; 7(1):4397.

PMID: 28667272 PMC: 5493638. DOI: 10.1038/s41598-017-04162-1.


References
1.
Bonfield T, Farver C, Barna B, Malur A, Abraham S, Raychaudhuri B . Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol. 2003; 29(6):677-82. DOI: 10.1165/rcmb.2003-0148OC. View

2.
Patel H, Belvisi M, Bishop-Bailey D, Yacoub M, Mitchell J . Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol. 2003; 170(5):2663-9. DOI: 10.4049/jimmunol.170.5.2663. View

3.
Lakatos H, Thatcher T, Kottmann R, Garcia T, Phipps R, Sime P . The Role of PPARs in Lung Fibrosis. PPAR Res. 2007; 2007:71323. PMC: 1940051. DOI: 10.1155/2007/71323. View

4.
Wei J, Ghosh A, Sargent J, Komura K, Wu M, Huang Q . PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One. 2010; 5(11):e13778. PMC: 2970611. DOI: 10.1371/journal.pone.0013778. View

5.
Steen V . Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005; 35(1):35-42. DOI: 10.1016/j.semarthrit.2005.03.005. View